Pu-erh tea polysaccharides decrease blood sugar by inhibition of α-glucosidase activity in vitro and in mice
Related Experiment Video
Updated: Apr 15, 2026

Comparative Study on the Polysaccharide Contents and Antioxidant Activities of Hippophae rhamnoides subsp. sinensis and Hippophae gyantsensis
Published on: August 15, 2025
Yea-Tyz Deng1, Shoei-Yn Lin-Shiau, Lie-Fen Shyur
1Institute of Biochemistry and Molecular Biology, College of Medicine, National Taiwan University, Taipei, Taiwan. jklin@csmu.edu.tw.
Abstract:
Type 2 diabetes is mainly induced by environmental factors such as being overweight, decreased physical activity and inbalanced energy metabolism, such as pancreatic beta-cell dysfunction and peripheral insulin resistance. Acarbose, a microbial carbohydrate and an alpha-glucosidase inhibitor, is currently a useful agent for attenuating type 2 diabetes. However, it is usually accompanied by many side effects, such as abdominal distention, flatulence, diarrhea and meteorism. These side effects may be caused by its strong inhibition of alpha-amylase, leading to the accumulation of several undigested carbohydrates. The bacteria residing in the colon can further ferment the undigested carbohydrate to release gas. Finding a new alpha-glucosidase inhibitor with a low inhibitory effect on alpha-amylase is highly anticipated. In this report we describe a group of carbohydrates found in pu-erh tea polysaccharide (PTPS) that can inhibit alpha-glucosidase but have less of an inhibitory effect on alpha-amylase. The preliminary experiments on mice indicate that PTPS might be better than acarbose at suppressing blood glucose after oral administration of a carbohydrate diet; it is recommended that further clinical trials are required in type 2 diabetes in future studies.
Related Concept Videos
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Dipeptidyl Peptidase 4 Inhibitors
Oral Hypoglycemic Agents: Biguanides and Glitazones
Hormones Regulating Blood Glucose
In addition to accelerating glucose uptake and utilization, insulin has...
Cell Specific Gene Expression
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

